Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belumosudil vs BAT in Refractory or Recurrent Chronic Graft Versus Host Disease
NCT07771439Phase 3Not yet recruiting
- Sponsor
- Sanofi
- Start
- Sep 2026
- Primary completion
- Sep 2029
01
Overview
A Phase 3 trial of belumosudil in chronic graft-versus-host disease (cGVHD), sponsored by Sanofi. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
belumosudil
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT07771439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07771439.